Dopamine-frusemide therapy in acute renal failure.

G. Graziani, S. Casati, A. Cantaluppi, A. Citterio, A. Aroldi, A. Scalamogna, D. Brancaccio, C. Ponticelli

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

In 16 patients with ARF and in three with hepatorenal syndrome we infused dopamine (3 micrograms/kg/min) and frusemide (10-15 mg/kg/day) for 6-24 hours. This treatment produced in all patients a significant diuresis and natriuresis without any modification of blood pressure, pulse rate, and central venous pressure. In three patients with hepatorenal syndrome diuresis was established during dopamine and frusemide infusion, but severe oliguria again reappeared when drug infusion was stopped. This experience suggests that this therapy may avoid fluid overload and hyperkalaemia in oliguric patients reducing the need for dialysis. It is also the first successful approach in the treatment of hepatorenal syndrome although its effect is transient.

Original languageEnglish
Pages (from-to)319-324
Number of pages6
JournalProceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association
Volume19
Publication statusPublished - 1983

Fingerprint

Furosemide
Hepatorenal Syndrome
Acute Kidney Injury
Dopamine
Diuresis
Oliguria
Natriuresis
Hyperkalemia
Central Venous Pressure
Therapeutics
Dialysis
Heart Rate
Blood Pressure
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Graziani, G., Casati, S., Cantaluppi, A., Citterio, A., Aroldi, A., Scalamogna, A., ... Ponticelli, C. (1983). Dopamine-frusemide therapy in acute renal failure. Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association, 19, 319-324.

Dopamine-frusemide therapy in acute renal failure. / Graziani, G.; Casati, S.; Cantaluppi, A.; Citterio, A.; Aroldi, A.; Scalamogna, A.; Brancaccio, D.; Ponticelli, C.

In: Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association, Vol. 19, 1983, p. 319-324.

Research output: Contribution to journalArticle

Graziani, G, Casati, S, Cantaluppi, A, Citterio, A, Aroldi, A, Scalamogna, A, Brancaccio, D & Ponticelli, C 1983, 'Dopamine-frusemide therapy in acute renal failure.', Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association, vol. 19, pp. 319-324.
Graziani, G. ; Casati, S. ; Cantaluppi, A. ; Citterio, A. ; Aroldi, A. ; Scalamogna, A. ; Brancaccio, D. ; Ponticelli, C. / Dopamine-frusemide therapy in acute renal failure. In: Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association. 1983 ; Vol. 19. pp. 319-324.
@article{8e9a308c420f497485d75fdd5da68755,
title = "Dopamine-frusemide therapy in acute renal failure.",
abstract = "In 16 patients with ARF and in three with hepatorenal syndrome we infused dopamine (3 micrograms/kg/min) and frusemide (10-15 mg/kg/day) for 6-24 hours. This treatment produced in all patients a significant diuresis and natriuresis without any modification of blood pressure, pulse rate, and central venous pressure. In three patients with hepatorenal syndrome diuresis was established during dopamine and frusemide infusion, but severe oliguria again reappeared when drug infusion was stopped. This experience suggests that this therapy may avoid fluid overload and hyperkalaemia in oliguric patients reducing the need for dialysis. It is also the first successful approach in the treatment of hepatorenal syndrome although its effect is transient.",
author = "G. Graziani and S. Casati and A. Cantaluppi and A. Citterio and A. Aroldi and A. Scalamogna and D. Brancaccio and C. Ponticelli",
year = "1983",
language = "English",
volume = "19",
pages = "319--324",
journal = "Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association",
issn = "0071-2736",

}

TY - JOUR

T1 - Dopamine-frusemide therapy in acute renal failure.

AU - Graziani, G.

AU - Casati, S.

AU - Cantaluppi, A.

AU - Citterio, A.

AU - Aroldi, A.

AU - Scalamogna, A.

AU - Brancaccio, D.

AU - Ponticelli, C.

PY - 1983

Y1 - 1983

N2 - In 16 patients with ARF and in three with hepatorenal syndrome we infused dopamine (3 micrograms/kg/min) and frusemide (10-15 mg/kg/day) for 6-24 hours. This treatment produced in all patients a significant diuresis and natriuresis without any modification of blood pressure, pulse rate, and central venous pressure. In three patients with hepatorenal syndrome diuresis was established during dopamine and frusemide infusion, but severe oliguria again reappeared when drug infusion was stopped. This experience suggests that this therapy may avoid fluid overload and hyperkalaemia in oliguric patients reducing the need for dialysis. It is also the first successful approach in the treatment of hepatorenal syndrome although its effect is transient.

AB - In 16 patients with ARF and in three with hepatorenal syndrome we infused dopamine (3 micrograms/kg/min) and frusemide (10-15 mg/kg/day) for 6-24 hours. This treatment produced in all patients a significant diuresis and natriuresis without any modification of blood pressure, pulse rate, and central venous pressure. In three patients with hepatorenal syndrome diuresis was established during dopamine and frusemide infusion, but severe oliguria again reappeared when drug infusion was stopped. This experience suggests that this therapy may avoid fluid overload and hyperkalaemia in oliguric patients reducing the need for dialysis. It is also the first successful approach in the treatment of hepatorenal syndrome although its effect is transient.

UR - http://www.scopus.com/inward/record.url?scp=0020688975&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020688975&partnerID=8YFLogxK

M3 - Article

VL - 19

SP - 319

EP - 324

JO - Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association

JF - Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association

SN - 0071-2736

ER -